Exogenous Testosterone Use and Central Serous Chorioretinopathy

Abstract

To investigate the clinical characteristics of central serous chorioretinopathy (CSCR) in the setting of exogenous testosterone use. Methods: Retrospective chart review of patients with a history of exogenous testosterone use and a diagnosis of CSCR at a large retina practice. Patient charts were reviewed for vision, clinical examination, and optical coherence tomography (OCT) results at each visit. Results: Four hundred eighty patients with a diagnosis of CSCR were identified, of which 7 patients had a history of exogenous testosterone use (1.46%). Of all, 0 of 7 patients reported any other steroid use. Ages ranged from 36 to 55 (mean, 46.57), and all were male. Only the right eye was involved in all 7 patients. Testosterone was discontinued in only 1 of the 7 patients. Six of the 7 patients had a visual acuity of 20/40 or better at last follow-up (range, 20/20-4/200). Three (43%) of the 7 had resolution of subretinal fluid at their last visit. The most common formulation of testosterone was for intramuscular injection. Conclusions: Exogenous testosterone use was reported in 1.46% of patients with CSCR compared to 0.8% in the general male population. The majority of patients in this study recovered 20/40 or better vision and 43% had resolution of subretinal fluid on OCT, suggesting a generally favorable prognosis for CSCR in the setting of testosterone supplementation.

Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone

“…2 Therapeutic options include discontinuation of offending agents such as steroids, psychotherapy for anxiety, photodynamic therapy (PDT), and argon laser though some cases may spontaneously resolve. 3 , 4 Studies of eplerenone and other mineralocorticoid receptor antagonist in the therapy of CSCR have shown mixed results. 5 , 6 Furthermore, the rarity of bCSCR has somewhat precluded definitive standard of care treatment options.…”